SEOUL -- Iksuda Therapeutics, a British biotech company that develops antibody-drug conjugates, will receive anti-cancer drug candidate materials from LegoChem Biosciences, a biopharmaceutical company in South Korea, for the development of blood cancer treatment.
Antibody-drug conjugates (ADCs) combine the targeting capabilities of monoclonal antibodies with the cancer-killing ability of cytotoxic drugs. LegoChem's proprietary platform enables the design of homogeneous plasma stable ADCs with the potential for improved payload delivery to cancer cells.
Iksuda was given exclusive rights to the global monopoly of ADC anti-cancer drug candidate materials LegoChem has jointly developed with Novimmune, a Swiss pharmaceutical development company. "We will work with Iksuda's clinical development subsidiary in Boston to quickly enter clinical trials," said LegoChem CEO Kim Yong-zu.
In April, Iksuda gained certain rights to LegoChem's ADC technology to develop and commercialize anticancer therapeutics. The South Korean company would receive milestone payments, which are paid when each milestone is achieved in clinical trials and commercialization, as well as royalties on the sales of any resulting ADC products.
© Aju Business Daily & www.ajunews.com Copyright: All materials on this site may not be reproduced, distributed, transmitted, displayed, published or broadcast without the authorization from the Aju News Corporation.